Diagnostics

Press release Biocartis Group NV: Biocartis Announces Conversion of a Portion of the Convertible Term Loan into New Shares and Discloses Outstanding Voting Securities

PRESS RELEASE: REGULATED INFORMATION  28 October 2022, 07:01 CEST Biocartis Announces Conversion of a Portion of the Convertible Term Loan...

Update: BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry Assays for Early Drug Development and Clinical Research

October 27, 2022 Press release BioPorto Exhibiting NGAL Biomarker at ASN Kidney Week – Antibodies, ELISA kits, and Clinical Chemistry...

Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL

AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...

Shineco, Inc. to Acquire Controlling Equity Interest in Changzhou Biowin Pharmaceutical Co., Ltd to Step into Point-of-Care Testing Industry

BEIJING, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc.(“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese...

SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in...

error: Content is protected !!